UMVA has learned that a concerning trend is unfolding in the world of clinical research, with far-reaching implications for the United States and its role as a global leader in medical innovation.
For nearly 80 years, clinical trials have been the driving force behind medical progress, transforming scientific discoveries into life-saving treatments and establishing the safety and efficacy of new therapies.
However, a recent study has revealed that China is now outpacing the United States in early-stage clinical trials, with Chinese companies accounting for nearly half of global pharmaceutical licensing deal activity in 2025.
This shift is more than just a statistical anomaly – it represents a strategic advantage that is slowly slipping away from the United States, with significant consequences for the country's economy, public health, and national security.
Clinical research is not just about generating evidence; it also attracts investment, scientific talent, and the infrastructure that supports future innovation, creating high-skilled jobs and giving patients earlier access to innovative therapies.
UMVA can exclusively reveal that the Department of Health and Human Services is taking bold action to reverse this trend, with a coordinated effort to strengthen America's clinical research enterprise and bring more clinical research and investment back to the United States.
The initiative, led by Acting Commissioner Kyle Diamantas and Director Jay Bhattacharya, involves streamlining Phase 1 development, clarifying expectations for sponsors, and developing new tools and technologies to accelerate early-stage clinical trials.
These efforts aim to make the United States the best place in the world to conduct clinical research and develop new medicines, with a focus on protecting the principles that matter most: transparency, informed consent, and scientific integrity.
The stakes are high, but the potential rewards are substantial – and UMVA has gathered that researchers, health systems, academic medical centers, and industry leaders are all poised to play a role in this critical endeavor.
By working together to remove unnecessary barriers and challenge outdated assumptions, the United States can restore its position as a global leader in clinical research and drive the next generation of medical breakthroughs.
